Group 1 - Hong Kong Stock Exchange announced that from November 24, Laplace (688726.SH) will be included in the Shanghai-Hong Kong Stock Connect [1] - Other companies such as Ruikeli (001285.SZ), Yunhan Chip City (301563.SZ), Jianda Zhixin (301584.SZ), United Power (301656.SZ), and Haochuang Ruitong (301668.SZ) will be included in the Shenzhen-Hong Kong Stock Connect [1]

Core Points - Hong Kong Stock Exchange announced that Laplace (688726.SH) will be included in the Shanghai-Hong Kong Stock Connect starting from November 24 [1] - Other companies such as Ruikem (001285.SZ), Yunhan Chip City (301563.SZ), Jianda Zhixin (301584.SZ), United Power (301656.SZ), and Haochuang Ruitong (301668.SZ) will be included in the Shenzhen-Hong Kong Stock Connect [1]

（编辑 袁冠琳） 证券日报网讯 建发致新11月19日在互动平台回答投资者提问时表示，福建地区目前是公司的一个重要 收入来源省份，公司在福建设立和运营十多家业务子公司，实现福建省医疗器械"属地配送"要求，直销 网络覆盖福建地区各地级市，终端客户以地区医院客户为主，经营品种主要包括高值耗材和IVD诊断产 品等。 ...

证券日报网讯11月19日晚间，建发致新（301584）发布公告称，公司及控股子公司未对合并报表外单位 提供担保。公司无逾期担保的情形，不存在涉及诉讼的担保及因担保被判决败诉而应承担损失等情形。 ...

Market Overview - The medical consumables supply chain SPD sector experienced a decline of 1.42% on November 19, with Ailong Technology leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Key stocks in the medical consumables supply chain SPD sector showed mixed performance, with Jianfa Zhixin rising by 3.19% to a closing price of 34.00, while several others, including Guoyao Yici and Jiuzhoutong, saw declines of 0.55% and 0.59% respectively [1] - The trading volume and turnover for Jianfa Zhixin were 180,800 hands and 620 million yuan, respectively [1] Capital Flow - The medical consumables supply chain SPD sector saw a net outflow of 99.05 million yuan from main funds, while retail investors contributed a net inflow of 74.72 million yuan [2] - Notable individual stock capital flows included Jianfa Zhixin with a net inflow of 70.39 million yuan from main funds, while Ailong Technology experienced a net outflow of 2.99 million yuan [3]

Market Overview - The pharmaceutical commercial sector declined by 1.33% on November 19, with Renmin Tongtai leading the losses [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Jianfa Zhixin rising by 3.19% to a closing price of 34.00, while Renmin Tongtai fell by 9.99% to 15.95 [2][1] - The trading volume for Jianfa Zhixin was 180,800 shares, with a transaction value of 620 million yuan [1] - Other notable stocks included Yifeng Pharmacy, which increased by 0.46%, and Shanghai Pharmaceuticals, which decreased by 0.39% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 436 million yuan from institutional investors, while retail investors saw a net inflow of 408 million yuan [2] - The data indicates that retail investors are more active in the sector despite the overall decline in stock prices [2] Individual Stock Capital Flow - Jianfa Zhixin had a net inflow of 70.39 million yuan from institutional investors, while Renmin Tongtai saw a significant outflow of 1.20 billion yuan from retail investors [3] - Other stocks like Guoyao Yizhi and Zhongyao Holdings also experienced mixed capital flows, with Guoyao Yizhi having a net inflow of 7.36 million yuan from institutional investors [3]

证券代码：301584 证券简称：建发致新 公告编号：2025-014 上海建发致新医疗科技集团股份有限公司 关于为下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 上海建发致新医疗科技集团股份有限公司（以下简称"公司"或"建发致 新"）及控股子公司提供担保总额超过公司最近一期经审计净资产100%，对资产 负债率超过70%的控股子公司预计担保金额超过公司最近一期经审计净资产50%， 前述担保均为对公司合并报表范围内子公司的担保，财务风险处于公司可控范围内， 提请投资者充分关注担保风险。 一、对外担保情况概述 根据公司经营发展战略、资金预算和资金安全等需要，自公司2024年年度股 东大会之日起，至2025年年度股东大会召开之日止，公司及控股子公司拟向各银行 等金融机构申请综合授信总额不超过人民币150亿元，以上事项已经公司2024年年度 股东大会和2025年第二次临时股东大会审议通过。 鉴于上述授信总额中部分授信额度的融资主体为公司控股子公司，为保障子公 司顺利申请授信额度，自公司2024年年度股东大会之日起，至202 ...

Market Overview - As of November 18, the Shanghai Composite Index closed at 3939.81 points, down 32.22 points, a decline of 0.81% [1] - The Shenzhen Component Index closed at 13080.49 points, down 121.52 points, a decline of 0.92% [1] - The ChiNext Index closed at 3069.22 points, down 35.98 points, a decline of 1.16% [1] High Turnover Stocks - A total of 100 A-shares had a turnover rate exceeding 20% on November 18, with six stocks, including Beikong Detection and C Hengkong, having turnover rates above 50% [1] - Beikong Detection (stock code: 920160) had a closing price of 26.50 yuan and a turnover rate of 88.46%, with a price increase of 295.52% [1] - C Hengkong (stock code: 688727) closed at 61.55 yuan, with a turnover rate of 81.36% and a price increase of 310.61% [1] - Other notable stocks with high turnover rates include C Nanshu (75.35% turnover, 224.78% increase) and Zhongfutong (53.96% turnover, -3.19% decrease) [1] Additional High Turnover Stocks - Other stocks with significant turnover rates include: - Xue Ren Group (50.33% turnover, -2.55% decrease) [1] - Jianglong Boat (46.42% turnover, -2.02% decrease) [1] - Xuanya International (44.73% turnover, 20.01% increase) [1] - Hongxiang Co. (44.63% turnover, 5.98% increase) [1] - The list continues with various companies showing diverse performance in terms of turnover and price changes [2][3][4]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.92% on November 18, with Yao Yigou leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance - Notable gainers included: - Ren Da Medical (603108) with a closing price of 15.97, up 2.90% and a trading volume of 278,200 shares, totaling 442 million yuan [1] - People's Tongtai (600829) with a closing price of 17.72, up 6.49% and a trading volume of 1,148,700 shares, totaling 1.902 billion yuan [1] - Major decliners included: - Yao Yigou (300937) with a closing price of 33.95, down 6.37% and a trading volume of 115,000 shares, totaling 396 million yuan [2] - Luhua Pharmaceutical (002788) with a closing price of 10.29, down 5.86% and a trading volume of 467,300 shares, totaling 489 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 706 million yuan from institutional investors, while retail investors contributed a net inflow of 705 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing while retail investors remained active [2] Individual Stock Capital Flow - Ren Da Medical (603108) had a net inflow of 49.2 million yuan from institutional investors, while retail investors saw a net outflow of 65.5 million yuan [3] - Yao Yigou (300937) experienced a significant net outflow of 560.4 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different stocks within the sector [3]

Group 1 - On November 17, Jianfa Zhixin's stock price dropped by 3.44%, with a trading volume of 481 million yuan [1] - The financing data shows that on the same day, Jianfa Zhixin had a financing purchase amount of 43.37 million yuan and a financing repayment of 49.50 million yuan, resulting in a net financing outflow of 6.13 million yuan [1] - As of November 17, the total balance of margin trading for Jianfa Zhixin was 131 million yuan, accounting for 7.50% of its circulating market value [1] Group 2 - As of September 30, Jianfa Zhixin had 38,000 shareholders, an increase of 151.60% compared to the previous period, while the average circulating shares per person decreased by 60.25% to 1,327 shares [2] - For the period from January to September 2025, Jianfa Zhixin achieved an operating income of 14.861 billion yuan, representing a year-on-year growth of 10.18%, and a net profit attributable to shareholders of 230 million yuan, which is a year-on-year increase of 45.01% [2] Group 3 - Jianfa Zhixin, established on August 30, 2010, is located at 288 Yangshupu Road, Yangpu District, Shanghai, and is primarily engaged in the direct sales and distribution of medical devices, as well as providing centralized operation services for medical consumables to terminal hospitals [1] - The main revenue composition of Jianfa Zhixin includes: vascular intervention (55.61%), surgical instruments (21.46%), in vitro diagnostic reagents (13.05%), medical equipment (6.24%), other medical devices (2.79%), SPD and other services (0.63%), and others (0.23%) [1]